Power Law company profile

Zymergen

Biotech & Life Sciences · Emeryville, United States · Founded 2013 · IPO 2021 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$226M

Market cap · 2026

Revenue

$17M

Latest reported FY

Investors

22 investors on Zymergen's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Seed 5 investors entered at this stage

Series A 6 investors entered at this stage

Series B+ 11 investors entered at this stage

Hanwha Asset Management

SoftBank Vision Fund

Baron Capital

ICONIQ Capital

Patent intelligence

$9M patent portfolio · 38 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with topic prominence vs same-sector peers.

Estimated portfolio value

$9M

4.2% of market cap · 289.3× smaller than top peer Illumina ($2.7B)

38 active patent families

Where Zymergen innovates Biological organismBioinformaticsMolecular biologyMicroorganismMicrobiology

Tech-focus vs peers

Where Zymergen concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Zymergen and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Zymergen on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo